Nasal cavity

Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal

Retrieved on: 
木曜日, 5月 23, 2024
Patient, Allergy, Therapy, Safety, NASAR, Social media, Allergic rhinitis, Nasal cavity, Pharmaceutical industry

Allergy’s social media reaches out to over 250’000 readers every month, and there are more than two million downloads of their articles per year.

Key Points: 
  • Allergy’s social media reaches out to over 250’000 readers every month, and there are more than two million downloads of their articles per year.
  • “The concept of Bentrio as a drug-free and preservative-free spray forming an efficient protective barrier within the nasal cavity appears to resonate well with allergic rhinitis sufferers.
  • From 2024 onwards, Altamira Medica expects sales to grow significantly, mainly driven by the launch of Bentrio in additional countries.
  • The Company expects to conclude partnering discussions and negotiations for distribution in the US, Europe and other key markets in the course of 2024.

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Retrieved on: 
水曜日, 5月 22, 2024
CTE, Principal, Patient, Metabolism, Baylor College of Medicine, Emergency medicine, Phase, Human, JAMA Cardiology, Chronic traumatic encephalopathy, Traffic, TBI, Common, Concussion, Emergency department, Baylor University, Efficacy, Animal, Blood, NCE, Nasal cavity, Biomarker, Post-concussion syndrome, DSM-IV codes, Brain, Research, Cardiology, Acute coronary syndrome, Traumatic brain injury, Pharmaceutical industry

SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William “Frank” Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department (“ED”).

Key Points: 
  • SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William “Frank” Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department (“ED”).
  • Dr. Peacock is currently the Vice Chair for Emergency Medicine Research at Baylor College of Medicine and a past Professor at the Cleveland Clinic Lerner College of Medicine.
  • “I am excited to join Oragenics as its Chief Clinical Officer at such an important and pivotal time in the company’s clinical program.
  • We are currently working with Avance Clinical, CRO, for our Phase II trial,” stated Michael Redmond, President of Oragenics.

EQS-News: Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico

Retrieved on: 
金曜日, 5月 3, 2024
Nose, Dry, Procter & Gamble, Immunology, Sneeze, Nasal cavity, Growth, Pharmaceutical industry

Korneuburg, Austria, 11 April 2024 – Marinomed Biotech AG (VSE:MARI) today announces the expansion of its Carragelose product portfolio with new launches in Austria and Mexico, paving the way for targeting new indications and access to key markets.

Key Points: 
  • Korneuburg, Austria, 11 April 2024 – Marinomed Biotech AG (VSE:MARI) today announces the expansion of its Carragelose product portfolio with new launches in Austria and Mexico, paving the way for targeting new indications and access to key markets.
  • Furthermore, following the successful market approval of a Carragelose nasal spray in Mexico by its distribution partner M8 Pharmaceuticals (an Acino company) last summer, the product is now available under the brand name Barlo®.
  • Targeting the Mexican market, which is Latin America’s second largest pharmaceutical market, this launch represents a significant revenue potential.
  • “With the market launch of our first Carragelose product in the Immunology segment and the product launch in Mexico, the second largest pharmaceutical market in Latin America, we have set important milestones in the ongoing expansion of our Carragelose portfolio.

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
木曜日, 3月 21, 2024
Research, LYRA, Common, Bronchitis, Disease, MF, New Drug Application, COVID-19, Patient, Smell, Network congestion, CRS, United, Nasal cavity, Pharmacotherapy, Investment, Clinical trial, Therapy, Safety, Sinusitis, ESS, FDA, Food, Pharmaceutical industry

WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.  

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  • LYR-220, a larger insert, is designed for CRS patients whose nasal cavity is enlarged due to previous ESS.
  • Cash, cash equivalents and short-term investments were $102.8 million as of December 31, 2023, compared to $102.6 million as of September 30, 2023.
  • The Company recorded an impairment charge of $1.6 million related to long-lived assets for the year ended December 31, 2023.

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Retrieved on: 
金曜日, 3月 15, 2024
Nosebleed, Research, Polyp (medicine), Vanderbilt University, Sciatica, Fluticasone, Education, Drainage, Disease, Incidence, Headache, Inflammation, Patient, Conditional sentence, Chronic obstructive pulmonary disease, Sinusitis, CRS, Standard of care, Quality of life, Migraine, Nasal cavity, Ear, ENT, Service, MPH, Nose, OPTN, FDA, Frustration, Food, Pharmaceutical industry

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Key Points: 
  • Chronic sinusitis (also called “chronic rhinosinusitis” or “CRS”) is one of the most common chronic diseases, affecting approximately 30 million adults in the United States.
  • Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine.
  • Chronic sinusitis is also one of the most common diagnoses in adult outpatient medicine.
  • Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually.

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Retrieved on: 
月曜日, 3月 18, 2024
Pharmaceutical, Health, Neurology, Clinical Trials, Depression, Metabolism, Brain, NCE, Acute stress disorder, Concussion, Veterans' affairs, Executive, Common, Inflammation, Patient, United States Congress, TBI, Foundation (nonprofit), Anxiety, CTE, University, Military personnel, Oxidative stress, Human, GMP, Nasal cavity, Traumatic brain injury, DSM-IV codes, Phase, Traffic, Swelling, FDA, Animal, Pentagon, Chronic traumatic encephalopathy, Phase II, Marcus Foundation, Medical device

Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.

Key Points: 
  • Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.
  • Dr. Kelly was also National Director of the Avalon Action Alliance TBI Programs for which the MIBH serves as the clinical coordinating center.
  • “I am excited to join Oragenics as its Chief Medical Officer at such an important and pivotal time in the drug development process.
  • Dr. Kelly has interacted with the FDA and clinical trials for brain injury throughout his esteemed career.

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Retrieved on: 
火曜日, 3月 5, 2024
Pharmaceutical, Health, Clinical Trials, Mental Health, CTE, Nasal administration, Active ingredient, Metabolism, IIA, Traumatic brain injury, Concussion, API, Nasal cavity, Animal, GMP, Common, Traffic, Safety, Patient, DSM-IV codes, Phase, Chronic traumatic encephalopathy, NCE, Brain, Pharmaceutical industry

The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion.

Key Points: 
  • The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion.
  • A 40-patient Phase I human study showed ONP-002 to be safe and well-tolerated.
  • Phase II patients will be recruited between the ages of 18-55 in the acute phase following concussion.
  • “Preclinical intranasal targeting of the brain has been shown to improve outcomes in animals and safety margin following concussion.

InventHelp Inventor Develops Product to Relieve a Cold and Mucus (RKH-555)

Retrieved on: 
月曜日, 2月 19, 2024
Mucus, Nasal cavity, Head, Sale, Common, SWEAT, Multimedia, Suite, COLD

I thought others could benefit from this process," said an inventor, from Rocky Mount, N.C., "so I invented the COLD SWEAT.

Key Points: 
  • I thought others could benefit from this process," said an inventor, from Rocky Mount, N.C., "so I invented the COLD SWEAT.
  • My design would help eliminate colds and sinus problems by breaking up mucus that is found in the sinus and chest cavities."
  • The patent-pending invention provides effective relief from a cold by breaking up mucus found in the sinus and chest cavities.
  • In doing so, it would emit moisture/heat into the nasal cavity and atop the chest in order to break up mucus associated with colds.

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Retrieved on: 
月曜日, 2月 5, 2024
Mental Health, Health, Neurology, Clinical Trials, General Health, Pharmaceutical, NCE, Memory, Concussion, CTE, Chronic traumatic encephalopathy, Traumatic brain injury, Nasal administration, Patient, Safety, Diagnosis, Brain, Animal, DSM-IV codes, Nasal cavity, Phase, Traffic, Common, Pharmaceutical industry

Oragenics has begun the final process of synthesizing and formulating the drug needed for its Phase II clinical trial.

Key Points: 
  • Oragenics has begun the final process of synthesizing and formulating the drug needed for its Phase II clinical trial.
  • We are excited to get the Phase II clinical trials underway,” commented Dr. James “Jim” Kelly, Neurologist and Executive Director of the Marcus Institute of Brain Health and an advisor on the planned phase II trial.
  • The drug has a large safety margin between dosages used in the animal toxicology program and those used in the Phase I study and planned for the upcoming Phase II clinical trial.
  • Post concussion syndrome is linked to long term disability and occurs in as high as 20% of concussed patients.

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Retrieved on: 
火曜日, 11月 21, 2023
Research, Patient safety, Nose, SILO, Brain, Anxiety, PTSD, Post-traumatic stress disorder, Nasal cavity, Silicon, Therapy, Area studies, Argyreia nervosa, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.

Key Points: 
  • “We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15.
  • Based on successful outcomes from these studies, we have selected Medspray’s Spray Technology for our formulation,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer’s disease and anorexia.
  • The drug dispersion through the nose to brain has been designed to optimize patient safety and therapeutic delivery.